Abstract
The current treatment regimen against drug susceptible tuberculosis (DS-TB) was defined by the 1980s. Since then the emergence of the global HIV pandemic and the escalation of drug resistant (DR-) forms of TB have presented new challenges for therapeutic research. Priority goals include shortening DS-TB treatment, improving DR-TB treatment and making combined TB-HIV therapy easier. To help achieve these goals, a range of new drugs and treatment strategies are currently being evaluated. Phase IIb and III clinical trials are ongoing to assess combinations involving the high-dose rifamycins, the 8-methoxyquinolones, a diarylquinoline (bedaquiline) and the nitroimidazoles. Other compounds (e.g. novel oxazolidinones and ethylenediamines) are at earlier stages of clinical development. Overall, there are grounds for optimism that recent advances will contribute towards achievement of new treatment regimens in the foreseeable future. However, long-term investment, political commitment and scientific endeavour are crucial to ensure that progress is sustained and the benefits of recent advances reach those in the greatest need.
Keywords: Bedaquiline (TMC-207), Delamanid (OPC-67683), Gatifloxacin, Moxifluxacin, PA-824, Rifampicin, Rifapentine, sterilising activity.
Current Respiratory Medicine Reviews
Title:New Drugs and Treatment Regimens
Volume: 9 Issue: 3
Author(s): Derek J. Sloan, Geraint R. Davies and Saye H. Khoo
Affiliation:
Keywords: Bedaquiline (TMC-207), Delamanid (OPC-67683), Gatifloxacin, Moxifluxacin, PA-824, Rifampicin, Rifapentine, sterilising activity.
Abstract: The current treatment regimen against drug susceptible tuberculosis (DS-TB) was defined by the 1980s. Since then the emergence of the global HIV pandemic and the escalation of drug resistant (DR-) forms of TB have presented new challenges for therapeutic research. Priority goals include shortening DS-TB treatment, improving DR-TB treatment and making combined TB-HIV therapy easier. To help achieve these goals, a range of new drugs and treatment strategies are currently being evaluated. Phase IIb and III clinical trials are ongoing to assess combinations involving the high-dose rifamycins, the 8-methoxyquinolones, a diarylquinoline (bedaquiline) and the nitroimidazoles. Other compounds (e.g. novel oxazolidinones and ethylenediamines) are at earlier stages of clinical development. Overall, there are grounds for optimism that recent advances will contribute towards achievement of new treatment regimens in the foreseeable future. However, long-term investment, political commitment and scientific endeavour are crucial to ensure that progress is sustained and the benefits of recent advances reach those in the greatest need.
Export Options
About this article
Cite this article as:
Sloan J. Derek, Davies R. Geraint and Khoo H. Saye, New Drugs and Treatment Regimens, Current Respiratory Medicine Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573398X113099990017
DOI https://dx.doi.org/10.2174/1573398X113099990017 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytochemicals, Medicinal and Food Applications of Shatavari (Asparagus racemosus): An Updated Review
The Natural Products Journal Tuberculosis: Challenges to Improve the Treatment
Current Clinical Pharmacology Predicting Experimental Properties of Proteins from Sequence by Machine Learning Techniques
Current Protein & Peptide Science Design, Synthesis, Pharmacological Evaluation, In silico Modeling, Prediction of Toxicity and Metabolism Studies of Novel 1-(substituted)-2-methyl- 3-(4-oxo-2-phenyl quinazolin-3(4H)-yl)isothioureas
Medicinal Chemistry A Remarkably Faster Approach Towards 1,2,3-Triazolyl Quinolines Via CuAAC in Water: Their Crystal Structure Analysis and Antibacterial Activities
Letters in Drug Design & Discovery Synthesis of Pyrophosphate-Containing Compounds that Stimulate VγVδ2 T Cells: Application to Cancer Immunotherapy
Medicinal Chemistry Homology Modeling of Adenosine A2A Receptor and Molecular Docking for Exploration of Appropriate Potent Antagonists for Treatment of Parkinsons Disease
Current Aging Science Cytokines as a Therapeutic Target for Allergic Diseases: A Complex Picture
Current Pharmaceutical Design Towards the Design and Development of Agents with Broad Spectrum Chemotherapeutic Properties for the Effective Treatment of HIV / AIDS
Current Medicinal Chemistry Antimicrobial Evaluation of 5-Substituted Aryl 1H-Tetrazoles
Medicinal Chemistry Preface
Current Medical Imaging Editorial [Hot Topic: Structure Based Drug Design (Guest Editor: K.V. Radha Kishan)]
Current Protein & Peptide Science Antimicrobial Potentials, Phytochemical Screening and Determination of Bioactive Compounds from Three Indian Folk Medicinal Plants
Current Bioactive Compounds Study of Stability of New Mutual Prodrugs with Antimycobacterial Activity
Current Organic Chemistry Anti-Microbial
Current Bioactive Compounds Biologic and Novel Therapy of the Inflammatory Bowel Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Mitochondrial and Plastid Functions as Antimalarial Drug Targets
Current Drug Targets - Infectious Disorders Benzimidazole: A Milestone in the Field of Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Genome-Scale Metabolic Model as a Virtual Platform to Reveal the Environmental Contribution of Methanogens
Current Biotechnology Formulation of Dry Powder Inhaler of Anti-tuberculous Drugs Using Spray Drying Technique and Optimization Using 23 Level Factorial Design Approach
Current Drug Therapy